Skip to main content

Table 1 Summary of pembrolizumab trials in malignant cancer

From: Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

Pathology

Trial

Phase

No of. patients

Treatment

mPFS (months)

mOS (months)

ORR (%)

Other outcomes

Melanoma

KEYNOTE-006

III

834

Pembrolizumab vs. Ipilimumab

5.5 vs. 2.8

–

34 vs. 12

–

NSCLC

KEYNOTE-010

II

–

Pembrolizumab vs. Docetaxel

5.2 vs. 4.1

17.3 vs. 8.2

 

–

 

KEYNOTE-189

III

616

Pembrolizumab + Pemetrexed and platinum vs. Placebo

8.8 vs. 4.9

–

62.9 vs. 49.4

–

HNSCC

KEYNOTE-012

Ib

60

Pembrolizumab

–

–

18

–

UC

KEYNOTE-052

II

370

Pembrolizumab

2.0

–

24

CR: 5%; DCR: 47%

 

KEYNOTE-045

III

542

Pembrolizumab vs. Paclitaxel and vinflunine

–

10.3 vs. 7.4

21.1 vs. 11.4

–

cHL

KEYNOTE-087

II

210

Pembrolizumab

72.4%*

99.5%*

69

CR: 22.4%

PMBCL

KEYNOTE-170

II

49

Pembrolizumab

–

62%*

41

CR: 14%; PR: 28%

DLBCL

Frigault et al

II

29

pembrolizumab

59%*

73%*

 

–

MM

Badros et al

II

48

Pembrolizumab + Pomalidomide and Dexamethasone

–

–

60

CR: 8%; PR: 19%

CC

KEYNOTE-028

Ib

24

Pembrolizumab

2.0

11.0

17

DCR: 30%

 

KEYNOTE-158

II

98

Pembrolizumab

2.1

9.4

13.3

DCR: 30.6%

Ovarian cancer

KEYNOTE-028

II

26

Pembrolizumab

1.9

13.8

11.5

SD: 26.9%

Endometrial cancer

Makker et al

II

23

Pembrolizumab + lenvatinib

–

–

39.6

DCR: 86.8%

TNBC

KEYNOTE-086

II

–

Pembrolizumab

2.0

9.0

5.3

DCR: 7.6%

MSI-H and dMMRS

KEYNOTE-164

II

63

Pembrolizumab

–

–

26.2

–

PM

Cedrés et al

Ib

25

Pembrolizumab

–

–

28

SD: 48%; DCR: 76%

GEJA

KEYNOTE-059

II

143

Pembrolizumab

–

–

13.3

DOR: 16.3 months

CRC

Ribas et al

Ib

–

Pembrolizumab + Oncolytic virus

–

–

62

CR: 33%

HCC

KEYNOTE-224

II

104

Pembrolizumab

–

12.9

17

CR: 1%; PR: 16%; DCR: 60%

  1. NSCLC: non-small cell lung cancer; HNSCC: head and neck squamous cell carcinoma; UC: urothelium carcinoma; cHL: classic Hodgkin lymphoma; PMBCL: primary mediastinal large B-cell lymphoma; DLBCL: diffuse large B cell lymphoma; MM: multiple myeloma; CC: cervical cancer; TNBC: triple-negative breast cancer; MSI-H and dMMRS: unresectable or metastatic solid tumors, including colorectal, endometrial and other gastrointestinal cancers; PM: pleural mesothelioma; GEJA: gastric or gastroesophageal junction adenocarcinoma; CRC: colorectal cancer; HCC: hepatocellular carcinoma; mPFS: median progression-free survival; mOS: median overall survival; ORR: objective response rate; CRR: complete response; PRR: partial remission; DCR: disease control rate; DOR: duration of response; SD: stable disease; *: PFS or OS rate. –: Not available